Model Integration and Configuration for Small Molecule Drug Clinical Trial Pre-screening

Data Characteristics

Small molecule drug clinical trial pre-screening data primarily originates from public clinical trial registries (e.g., ClinicalTrials.gov, WHO ICTRP) and medicinal chemistry databases (e.g., PubChem, ChEMBL). Data updates typically occur weekly or monthly, depending on each database's release cycle. Document structures are predominantly structured tables. These tables include trial design (study type, phase, inclusion criteria, exclusion criteria), drug information (chemical structure, mechanism of action, target), disease characteristics (ICD-10 codes, biomarkers), and patient demographics (age, sex, race). Field units are standardized: dose units are mg or μg, time units are days or weeks, and age units are years. Some data also exists as unstructured text, such as trial protocol descriptions and adverse event reports, requiring information extraction.

Constraints on Model Integration and Configuration

The structured nature of small molecule drug data prioritizes efficient parsing and indexing of structured data during model integration. Standardized field units require strict unit unification and validation during data preprocessing. This prevents model misjudgments due to inconsistent units. For example, if dose fields are not unified to standard units, it directly impacts the model's judgment of dose-response relationships. Varying update frequencies mean knowledge base synchronization strategies must balance real-time updates with resource consumption. Incremental update mechanisms can be used for frequently updated registration information. Unstructured text, such as inclusion/exclusion criteria descriptions, demands high text understanding and information extraction capabilities from the LLM. This requires configuring appropriate prompt engineering and RAG retrieval strategies. Chemical structure data, often stored in SMILES or InChI format, may require specialized preprocessing modules or embedding layers during model configuration to support similarity search or inference based on chemical features.

Configuration Settings

Common Pitfalls

• The model cites non-existent trial IDs or drug names when answering clinical trial inclusion criteria. This typically results from LLM hallucination, failing to effectively use real data retrieved from the knowledge base, or insufficient clarity in prompt constraints on citation format.
• When filtering patients within a specific dosage range, the model's output does not match expectations. This can occur if dose field units were not unified during data preprocessing, leading to errors in model comparisons.
• The AI model selection interface in the workflow does not display integrated privately deployed models. This may relate to incorrect network configuration or API key passing methods for external LLM services in FastGPT within a Docker environment.

Verification

• Submit a pre-screening request with detailed patient characteristics for a specific disease and drug. Cross-reference the model's output list of eligible trials, checking for expected matches with known trials.
• Validate the model's understanding of complex inclusion/exclusion criteria, such as conditions involving "AND/OR" logic. Verify the model's judgment results under different condition combinations to ensure logical correctness.
• Examine the knowledge base paragraph sources cited in the model's answers. Ensure citation IDs and content align with actual data in the knowledge base, especially for critical numerical information like dosage and treatment duration.

The values provided are common starting points and should be measured against the reader's own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.